Glioma is the most common form of central nervous system (CNS) neoplasm that originates from glial cells. In the United States, there are six cases of gliomas diagnosed per 100,000 people every year. Gliomas are very diffusely infiltrative tumors that affect the surrounding brain tissue. Glioblastoma is the most malignant type while pilocytic astrocytomas are the least malignant brain tumors.
In the past, these diffuse gliomas were classified into different subtypes and grades based on histopathologies such as a diffuse astrocytoma, oligodendrogliomas, or mixed gliomas/oligoastrocytomas. Recently, gliomas were classified based on molecular and genetic markers. These advances have more specific prognostic and therapeutic benefits for patients with gliomas. In addition to molecular and genetic markers, gliomas are classified in grade I to IV based on the degree of proliferation indicated by the mitotic index and the presence or absence of necrosis.
There are three common types of gliomas, which are classified based on the phenotypic cell characteristics: astrocytomas, ependymomas, and oligodendrogliomas. These cell gliomas are further classified to low grade, atypical, and high-grade tumors based on cell morphology, mitotic activities, and molecular marker. The World Health Organization (WHO) grading system utilizes molecular markers that have shown to have significant prognostic and therapeutic implications.
There is an estimation of 80,000 newly diagnosed cases of primary brain tumor each year in the United States. Around one-fourth of which (i.e. 20,000) are gliomas. The total number of glioblastomas diagnosed each year is around 12,000 cases (approximately 15% of total newly diagnosed brain tumors).
Headaches are the most common initial presenting symptom of patients with glioma. The pathophysiology of headaches is theorized to be the result of tumor growth that places a mass effect on surrounding tissue. The mass effect, in turn, leads to pressure in the microvasculature and leads to edema. Depending on the location of the tumor in the brain, the mass effect leads to signs of a brain tumor. For example, frontal lobe tumors can present with behavioral changes while dominant temporal lobe tumors can present with receptive speech problems. Other symptoms related to mass effects include nausea, vomiting, and change in vision, Seizures are the second most common symptom of presentation. The pathophysiology of seizures is attributed to tumor irritation to the cerebral cortex that leads to focal or generalized seizures. Other presenting symptoms of gliomas are tingling sensations, weakness, difficulty ambulation, and in rare cases, patients can present in a comatose state due to hemorrhage within the tumor which leads to an acute herniation syndrome.
There are some epidemiological studies suggesting that ionizing radiation and some radiofrequency waves can increase the chance of redeveloping high-grade gliomas. However, these studies lack specificity to gliomas. However, advances in the molecular biology and genetics of gliomas have revealed that low-grade gliomas transform into high-grade gliomas by altering the genetic makeup of low-grade gliomas. Therefore, one can hypothesize that environmental and treatment-related toxicokinetics can play a role in the transformation of low-grade gliomas.
The most common presentations in brain gliomas are headaches, nausea, vomiting, seizures, and in more advanced cases weakness or altered mental status. The neurological examination of these patients can be normal or present different degrees of focal weakness, sensory deficits, or in a severe situation altered mental status due to an acute mass effect resulted from the tumor swelling.
The following imaging diagnostics are appropriate in the setting of history and physical examination suggestive of brain tumors:
The WHO classification of gliomas is used to guide glioma treatment. As indicated in the classification, most patients require surgical intervention via gross total resection or biopsy.
2016 WHO Grades of Gliomas
2. Other astrocytic tumors
3. Ependymal tumors
Treatment of Gliomas
2. Chemoradiation: Currently, Stupp protocol is a standard of care for Grade III-IV gliomas. The protocol consists of radiotherapy and concomitant chemoradiation using a total of 60 Gray to 2 Gray per daily fraction over 6 weeks and temozolomide.
3. Treatments for Recurrence: Options for recurrent gliomas include re-operation with Gliadel wafers and targeted therapy such as angiogenesis inhibitors or immunotherapy. The effectiveness of all these adjuvants therapies is in development.
4. Others Treatments: High-grade glioma patients are prone to seizures, malignant edema, and complication related immobility. Therefore, these patients need antiepileptic medications, deep venous thrombosis (DVT) prophylaxis, and steroids before, during, and after the course of treatments to avoid cerebral edema.
The differential diagnoses include:
The prognosis of gliomas depends on several factors including:
The patients should be educated on the importance of regular follow-up visits, having medications on time, and regarding driving restrictions.
Gliomas in general, specifically glioblastomas, are very difficult to treat. Despite advances in understanding the molecular biology and genetics of gliomas, no significant impact has been made toward preventing the lethality of high-grade gliomas. Therefore, there is a continuing need for clinical and basic science investigations to advance the care of this lethal disease.
Patients with gliomas require an interprofessional treatment approach. Neurosurgeons, neuro-oncologists, radiation oncologists, and other health professionals will play to enhance patient care and optimum outcome.
|||Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system., Jiang H,Cui Y,Wang J,Lin S,, Oncotarget, 2017 Mar 21 [PubMed PMID: 27888628]|
|||Lopes MBS, The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta neuropathologica. 2017 Oct; [PubMed PMID: 28821944]|
|||European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas., Weller M,van den Bent M,Tonn JC,Stupp R,Preusser M,Cohen-Jonathan-Moyal E,Henriksson R,Le Rhun E,Balana C,Chinot O,Bendszus M,Reijneveld JC,Dhermain F,French P,Marosi C,Watts C,Oberg I,Pilkington G,Baumert BG,Taphoorn MJB,Hegi M,Westphal M,Reifenberger G,Soffietti R,Wick W,, The Lancet. Oncology, 2017 Jun [PubMed PMID: 28483413]|
|||Zhang S,William C, Educational Case: Histologic and Molecular Features of Diffuse Gliomas. Academic pathology. 2020 Jan-Dec; [PubMed PMID: 32284966]|
|||Kinslow CJ,Garton ALA,Rae AI,Marcus LP,Adams CM,McKhann GM,Sisti MB,Connolly ES,Bruce JN,Neugut AI,Sonabend AM,Canoll P,Cheng SK,Wang TJC, Extent of resection and survival for oligodendroglioma: a U.S. population-based study. Journal of neuro-oncology. 2019 Sep; [PubMed PMID: 31407129]|
|||Kristensen BW,Priesterbach-Ackley LP,Petersen JK,Wesseling P, Molecular pathology of tumors of the central nervous system. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Aug 1; [PubMed PMID: 31124566]|
|||Childhood Astrocytomas Treatment (PDQ®): Health Professional Version 2002; [PubMed PMID: 26389382]|
|||Muthusamy RK,Mehta SS, Chordoid Glioma of the Third Ventricle. Neurology India. 2019 Jul-Aug; [PubMed PMID: 31512680]|
|||O'Halloran PJ,Amoo M,Dablouk MO,Beausang A,MacNally S, Angiocentric glioma: Drop Metastases to the Spinal Cord. World neurosurgery. 2020 Apr; [PubMed PMID: 31953098]|
|||Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme., Cohen MH,Johnson JR,Pazdur R,, Clinical cancer research : an official journal of the American Association for Cancer Research, 2005 Oct 1 [PubMed PMID: 16203762]|